Molekule Case Studies

MOLEKULE CASE STUDIES

FROM THERAPY AREA X – TIMELINE OVERVIEW

Therapy-Area-x-timeline-2

MOLEKULE CASE STUDIES: IN SUPPORT OF A

TOP – 10 MNC
ETHICAL PHARMA

SITUATION

Our client faced near-term direct competition from both generic and novel FDC HIV ARV assets

ACTION

In support of a Top-10 ethical MNC biopharma player, Molekule conducted a comprehensive landscape monitoring of the HIV market for FDC ARV generics – either direct ANDA competitors to established brands of novel FDCs of generics components. We worked with a Director of Strategic Planning to assess the impact and implications of generic threats to established ARV agents, as well as novel FDC ARV agents.

MOLEKULE CONDUCTED COMPREHENSIVE LANDSCAPE MONITORING

Inclusive of:

• Congress Coverage
• KOL Interviews
• Competitor interviews
• Regulatory Stakeholder Interviews
• Payer Interviews

RESULTS

Molekule accurately identified a short list of key generic competitors poised to enter the FDC ARV market. Accordingly, our client was able to correlate its manufacturing of product to scale with the forthcoming genericization, conterring significant cost savings to our client.

TOP – 5 MNC
ETHICAL PHARMA

SITUATION

Our client sought high value antibiotic targets for in-licensing, acquisition and/or partnership.

ACTION

Molekule was engaged by a Top-5 MNC U.S.-based ethical pharmaceutical player to conduct a targeted assessment of the market dynamics and associated implications of novel antibiotics and associated potential licensing partnerships/ agreements in select markets including the U.S., Big-5 EU and Japan. Our client was an Associate Director of Business Development and Licensing and the overall engagement enabled our client to elucidate BD&L opportunities in the U.S., Big-5 EU and Japan markets for key antibiotic assets.

MOLEKULE CONDUCTED A BUSINESS DEVELOPMENT & LICENSING DUE DILIGENCE TARGETED CI ASSESSMENT

Inclusive of:

• KOL Interviews
• BD&L Target Interviews
• Congress Coverage

RESULTS

Molekule assessed a wide-spanning universe of potential BD&L targets and opportunities. We winnowed this universe to high and moderate potential opportunities. Thereafter, we developed a short-list of warm, high potential BD&L targets, which our client’s BD team pertomed internal due diligence and negotiations.

SPECIALTY
BIOPHARMA

SITUATION

Our client is engaged in the highly competitive IBD space and needed a focused and robust universe of KIT/Qs answered to better address emerging competitive dynamics.

ACTION

Molekule was engaged by a specialty gastroenterology player to conduct comprehensive congress coverage of the UEGW and ACG congresses in support of a blockbuster anti-TNF asset. Our client was a Senior Manager of Global Competitive Intelligence; engaging together, Molekule depicted clear answers to the client’s high, medium and low priority KIT/Qs, enabling the client company to position itself for robust success in the gastroenterology space, forward-looking in the U.S. and EU.

MOLEKULE WAS ENGAGED TO CONDUCT COMPREHENSIVE CONGRESS COVERAGE

Inclusive of:

• Congress Coverage
• Competitor interviews
• KOL Interviews

RESULTS

Molekule furnished our client high impact, accurate, timely and actionable strategic insight and intelligence leveraging congressess as venues flush with high value human source resulted in our client hardening competitive pinch points and elucidating blind spots.

MAJOR EU
BIOPHARMA

SITUATION

Our client wanted to understand competitive commercial strategies across global mid-sized biopharmaceutical players.

ACTION

Molekule was engaged by a large cap EU-based biopharmaceutical player to conduct a targeted assessment of novel strategic implementation models across mid-sized (i.e.- $300MM – $750MM market capitalization) biopharmaceutical players approaches to global market access and go-to-market strategy. Our client was a Senior Director of Marketing Analytics and Business insights.

MOLEKULE WAS ENGAGED TO CONDUCT A TARGETED CI ASSESSMENT MARKET ACCESS & GO-TO-MARKET STRATEGY ASSESSMENT

Inclusive of:

• Competitor interviews
• Internal Stakeholder Interviews
• KOL Interviews

RESULTS

Partnered together, Molekule and client developed keen insights and market intelligence regarding middle market capitalization competitors’ global market access and go-to-market access strategies, worldwide.

TOP – 3 MNC
BIOPHARMA

SITUATION

Our client sought market intelligence regarding competitive blunting strategies and tactics across key players and markets.

ACTION

Molekule was engaged by a global Top-3 ethical MNC biopharmaceutical player to conduct an elucidation of competitor strategies and tactics that are leveraged to driver and/or blunt market uptake and traction of novel biopharmaceutical products in North America, LATAM and the Big-5 EU markets. Our client was a Senior Manager of Global Commercial Insights.

MOLEKULE CONDUCTED COMPETITIVE LANDSCAPE MONITORING & CONGRESS COVERAGE

Inclusive of:

• Competitor interviews
• Internal Stakeholder Interviews
• KOL Interviews

RESULTS

Molekule developed clear, concise and actionable intelligence regarding the drivers and key factors leverageable to blunt market uptake and traction of competitor novel biopharmaceutical assets in North America, LATAM and Big-5 EU markets.

BOUTIQUE
BIOTECH

SITUATION

Our client sought overall firm-wide diversification via a new business and commercial model.

ACTION

Molekule was engaged by a niche/specialist U.S.- based biopharmaceutical company with a mid-sized market capitalization to develop a new business plan for strategic diversification from a “one-stop-shop” biopharmaceutical player into a diversified specialty pharmaceutical company. Our client was a VP of Global Strategy.

MOLEKULE CONDUCTED A COMPETITIVE CORPORATE STRATEGY ASSESSMENT

Inclusive of:

• Internal Stakeholder Interviews
• External Competitor Stakeholder Interviews
• Subject Matter Expert Interviews
• Therapy Area Expert Interviews

RESULTS

Partnered together, Molekule and client developed a concerted growth and development plan including decisive diversification for the client across three (3) key therapeutic areas of potential pipeline growth opportunity.